BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections
Source: SeekingAlpha
2025-11-12 10:32:20 ET
More on BiomX
- BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on BiomX
- Historical earnings data for BiomX
- Financial information for BiomX
Read the full article on Seeking Alpha
For further details see:
BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections
Chardan Healthcare Acquisition Corp.
NASDAQ: PHGE
PHGE Trading
-11.65% G/L:
$6.37 Last:
70,372 Volume:
$7.35 Open:
PHGE Latest News
March 09, 2026 09:00:00 am
BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
December 08, 2025 07:30:00 am
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
PHGE Stock Data
$10,193,182
1,246,130
N/A
9
N/A
Biotechnology & Life Sciences
Healthcare
IL
Ness Ziona
